Boehringer Ingelheim has put a hold on its Phase I work with a BACE inhibitor for Alzheimer's, marking the latest in a series of missteps for this category of therapeutics, which has emerged as one of the key arenas in the field.
Boehringer Ingelheim's global restructuring--prompted by the German pharma's sales struggle--is now manifesting itself in Connecticut, where the company is laying off staffers in Ridgefield.
Struggling with falling sales, Boehringer Ingelheim is trimming its workforce in Connecticut, which accounts for about 2,700 staffers altogether.
Partners Eli Lilly and Boehringer Ingelheim picked up FDA approval for a first-of-its-kind diabetes treatment, combining two existing drugs into a single tablet.
At Sanofi, 72% of its drugs under development are biologics and half of those are monoclonal antibodies (mAbs). But instead of building a new plant right now, the French drugmaker will lean on Boehringer Ingelheim for additional mAb capacity.
Sanofi and Regeneron are hard at work on a number of promising monoclonal antibodies, but Sanofi needs more manufacturing capacity to produce them. Instead of building its own like some of its peers, the French company has struck a deal to tap into a Boehringer Ingelheim plant in Germany.
Boehringer Ingelheim is considering severing more of its ties to drug production in Ohio. The latest asset to go up for sale is Roxane Labs, a Columbus, Ohio-based generics business that also produces some of Boehringer's patent-protected drugs.
Boehringer Ingelheim has been struggling under the weight of slumping sales and patent expirations for some of its top products, shedding jobs and unloading assets to lighten its load. The German company could be set to slim down further, as it considers selling its U.S.-based generics unit for up to £2 billion ($2.33 billion) to focus on developing new drugs.
If you've watched television lately, you know that Pfizer and Bristol-Myers have been spending a lot of money on advertising to back their new anticoagulant, Eliquis. So have rival Boehringer Ingelheim, with its Pradaxa drug, and Bayer and Johnson & Johnson with Xarelto.
German diagnostic imaging outfit nanoPET Pharma is teaming up with Boehringer Ingelheim to develop diagnostic agents for preclinical drug development, building on a previous relationship between the two companies and opening the door for future collaboration.